This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
by Zacks Equity Research
Roche (RHHBY) announces that it will acquire Flatiron Health to accelerate development and delivery of breakthrough drugs for cancer patients.
AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan
by Zacks Equity Research
AbbVie (ABBV) announces a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buyback program by the board.
Roche's Rituxan Gets Priority Review for Label Expansion
by Zacks Equity Research
FDA accepts sBLA and grants priority review for Roche Group's (RHHBY) leukemia drug Rituxan.
Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?
by Zacks Equity Research
ImmunoGen (IMGN) advances with lead ovarian cancer candidate, mirvetuximab soravtansine. Moreover, combo therapies with the candidate for the indication are underway.
Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis
by Zacks Equity Research
Novartis' (NVS) psoriasis drug, Cosentyx is already approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.
Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) Rolontis meets primary endpoint in a phase III study for management of neutropenia in early stage breast cancer.
Roche Reports Positive Data From Tecentriq-Avastin Study
by Zacks Equity Research
Roche reported positive results from a phase III study on the combination of immunotherapy drug Tecentriq and oncology drug Avastin.
Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft
by Zacks Equity Research
Amgen (AMGN) misses expectations for both earnings and sales and also issues a lower-than-expected sales guidance for 2018. Shares decline in after-hours trading.
Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa
by Zacks Equity Research
Roche reported strong sales for 2017 buoyed by performance of new drugs ??? Tecentriq, Alecensa and Perjeta which offset the decline in Tarceva and Avastin.
Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label
by Zacks Equity Research
Amgen (AMGN) gains consent from the Committee for Medicinal Products for Human Use to add overall survival data from a phase III study on the label of its cancer drug, Kyprolis.
Why Earnings Season Could Be Great for Amgen (AMGN)
by Zacks Equity Research
Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pfizer (PFE) Stock Falls Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Pfizer (PFE) beats expectations for both earnings and revenues in Q4 and issues an upbeat guidance for 2018. However, shares decline in pre-market trading.
Roche Gets Breakthrough Therapy Designation For ASD Drug
by Zacks Equity Research
Roche obtains Breakthrough Therapy Designation for its experimental drug oral medicine balovaptan from the FDA which is likely to expedite the review and development of the drug.
Meredith (MDP) Hikes Dividend 4.8% Just Ahead of Q2 Earnings
by Zacks Equity Research
Meredith (MDP) has recently declared a dividend hike of 4.8% to 54.5 cents per share, marking 25th straight year of dividend hike.
Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors
by Zacks Equity Research
Novartis' oncology portfolio gets a further boost with the FDA approval of Lutathera for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.
Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion
by Zacks Equity Research
Roche announced that it its hemophilia drug Hemlibra obtained a positive opinion from the Committee for Medicinal Products for Human Use in Europe.
Will Amgen (AMGN) Benefit From Growth Drugs in Q4 Earnings?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Novartis Gets Spark Therapeutics' Luxterna License Outside US
by Zacks Equity Research
Novartis has obtained the marketing rights for Luxterna oustide the United States thereby building upon its gene therapy treatments which includes Kymriah.
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
by Zacks Equity Research
Novartis (NVS) announced strong results for the fourth quarter as earnings and sales both beat estimates driven by Cosentyx and Entresto sales which more than offset the decline in Gleevec sales.
Novartis Announces Positive Results on Migraine Candidate
by Zacks Equity Research
Novartis announced positive results on migraine candidate, AMG334, from the phase IIIb study. The candidate is being developed in collaboration with Amgen,
Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb
by Zacks Equity Research
Amgen's (AMGN) antibody Aimovig meets all primary and secondary endpoints in a phase IIIb study on patients with episodic migraine, who have failed multiple prior preventive treatments.
Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?
by Arpita Dutt
Does Celgene's (CELG) decision to acquire Juno signal the revival of biotech M&A activity after a slow 2017?
Merck Reports Positive Phase III Liver Cancer Data on Keytruda
by Zacks Equity Research
Merck (MRK), announces first time results from the phase II study evaluating the use Keytruda in patients with advanced hepatocellular carcinoma (HCC), previously treated with sorafenib.
What's in the Cards for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Novartis has an excellent track record. We expect investors to focus on the performance of new drugs and revival of Alcon business.
The Zacks Analyst Blog Highlights: UnitedHealth, Amgen, United Technologies, CSX and General Dynamics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Amgen, United Technologies, CSX and General Dynamics